Navigation Links
New Jefferson trial to test radiation-emitting beads against advanced liver cancer
Date:2/12/2008

(PHILADELPHIA) Liver cancer specialists at Jeffersons Kimmel Cancer Center in Philadelphia are beginning an 18-month study of a new treatment for liver cancer. The therapy entails injecting tiny beads that emit small amounts of radiation into the livers main artery while also blocking the blood supply feeding the cancers growth.

The technique, called radioembolization, has been approved by the federal Food and Drug Administration for use in inoperable liver cancer. This is the first time that the particular technology, called SIR-Spheres microspheres, which is FDA-approved for treating colon cancer that has spread to the liver, is being studied in patients with hepatocellular carcinoma, or primary liver cancer (cancer that originates in the liver). The trial, which is led by Brian Carr, M.D., FRCP, Ph.D., professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, includes patients from the University of Texas M.D. Anderson Cancer Center in Houston and the University of Pittsburgh.

According to Dr. Carr, who is chief of the liver tumor program at the Kimmel Cancer Center and Thomas Jefferson University Hospital, the technique uses approximately 30-times more beads than other types or radioembolization. The teams plan to enroll 10 patients initially, and perhaps as many as 40 altogether. No one knows if radioembolization will be better than just radiation, even though there are theoretical grounds for it, he notes.

In the form of radioembolization being tested, millions of tiny beads or microspheres containing the radioactive isotope Yttrium-90 are injected through a catheter directly into the livers hepatic artery, which also supplies blood to tumors. The microspheres, in addition to blocking blood flow to the tumor, emit targeted radiation directly to the cancer, sparing healthy tissue.

Dr. Carr and his colleagues are encouraged by results from a recent clinical trial showing the effectiveness of a similar technique against advanced liver cancer. Reporting recently in the journal Hepatology, Dr. Carr and physicians at Northwestern University in Chicago found that injecting another type of Yttrium-90-containing beads (TheraSphere) was effective in treating inoperable liver cancer even in patients whose portal vein was blocked by tumor. The treatment, he says, was as good as or better than using the current standard called chemoembolization, which involves directly injecting chemotherapy drugs into the liver through the hepatic artery. Because it involves dangerous, cell-killing drugs, he notes, doctors have sought liver cancer treatments that have fewer toxic effects.

The treatment doesnt cure the cancer, but has been shown to often shrink tumors and help patients live longer. It can also be used for patients who have previously failed chemotherapy. This extends the numbers of patients who can be treated with this much safer treatment, he says. Using TheraSphere is just as safe with or without portal vein thrombosis, so it looks like its a wonderful new treatment. Its much safer because these patients dont get chemotherapy side effects, such as nausea, hair loss and they generally dont need to be in the hospital except for the day of treatment, which is usually every three months.

The immediate objective is to get patients to live longer and ultimately, a cure, Dr. Carr says. Right now the choices are surgery and or transplant. Ideally, if the radioembolization trial is successful, many of these patients would have their liver tumors shrunken to the point where surgery is possible. Some may be able to have a transplant. It would be a significant contribution to the field if we could downstage the tumors so we could do more transplants, which is the only cure.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
2. Jefferson immunology researchers halt lethal rabies infection in brain
3. Jefferson radiation oncologists use real-time system to plant seeds against cancer
4. Jefferson researchers find personalized interventions key to improving colon cancer screening rates
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
7. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... , ... Looking for a last-minute Valentine’s Day gift for the special someone ... massage, whether administered by a professional masseuse or a loved one, can bring substantial ... Multiple Specialties in Podiatry (ABMSP) has taken the upcoming Valentine’s Day as an ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... the 2015 Best in KLAS: Software & Services for HIT Implementation Support & ... KLAS report independently ranks vendor performance by healthcare executives, managers and clinicians representing ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a ... drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect for ... includes a 3D slideshow environment with 1 to 5 focus points per scene, stage ...
(Date:2/5/2016)... ... 05, 2016 , ... Calls Blacklist has just been updated by mobile app ... the developer has fixed known bugs within the app. Calls Blacklist allows its users ... not consuming any of their device’s battery power or memory. It provides a powerful ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 5, 2016 --> ... report "Fetal (Labor & Delivery) and Neonatal Care Equipment ... Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) ... report studies the global market over the forecast period ... USD 6.28 Billion in 2015 and is poised to ...
(Date:2/5/2016)... PUNE, India , February 4, 2016 ... , Spain , UK, and Israel ... of Type 1, 2, and 3 GD, segmented by age and sex ... and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and ... France , Germany , ...
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation ... innovations for structural heart disease and critical care monitoring, ... share repurchase (ASR) agreement with Morgan Stanley & Co. ... This repurchase is part of the Company,s previously authorized ... Company,s common stock.  --> ...
Breaking Medicine Technology: